New pill tested as potential alternative for leukemia treatment
NCT ID NCT05623774
Summary
This study tested a new drug called IkT-001Pro to see if it works similarly in the body to the standard drug, imatinib, used to treat a type of blood cancer called CML. Researchers gave different doses of both drugs to healthy volunteers to compare safety and how the body absorbs them. The goal is to see if the new drug could be a future alternative treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.